Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival—a propensity score cohort study
Breast Cancer Research and Treatment · 2024
DOI: 10.1007/s10549-024-07274-1 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Sergi Fernandez-Gonzalez und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Multidisciplinary Breast Cancer Unit, Hospital Universitari Bellvitge, Idibell, c/ Feixa Llarga s/n. Hospitalet de Llobrega…. Hauptthemen laut MEDLINE: Sentinel Lymph Node Biopsy, Breast Neoplasms, Neoadjuvant Therapy, Axilla. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitat de Barcelona.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
In patients with clinically lymph node-negative (cN0) breast cancer, performing sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NACT) has been preferentially embraced in comparison to before NACT. However, survival outcomes associated with both strategies remain understudied. We aimed to compare the axillary lymphadenectomy (ALND) rate, disease-free survival (DFS), and overall survival (OS), between two strategies.
Methods
We included 310 patients in a retrospective observational study. SNLB was performed before NACT from December 2006 to April 2014 (107 cases) and after NACT from May 2014 to May 2020 (203 patients). An inverse probability of treatment weighting (IPTW) method was applied to homogenize both groups. Hazard ratios (HR) and odd ratios (OR) are reported with 95% confidence intervals (95%CI).
Results
The lymphadenectomy rate was 29.9% before NACT and 7.4% after NACT ( p < 0.001), with an OR of 5.35 95%CI (2.7–10.4); p = .002. After 4 years of follow-up, SLNB after NACT was associated with lower risk for DFS, HR 0.42 95%CI (0.17–1.06); p = 0.066 and better OS, HR 0.21 CI 95% (0.07–0.67); p = 0.009 than SLNB before NACT. After multivariate analysis, independent adverse prognostic factors for OS included SLNB before NACT, HR 3.095 95%CI (2.323–4.123), clinical nonresponse to NACT, HR 1.702 95% CI (1.012–2.861), and small tumors (cT1) with high proliferation index, HR 1.889 95% (1.195–2.985).
Conclusion
Performing SLNB before NACT results in more ALND and has no benefit for patient survival. These findings support discontinuing the practice of SLNB before NACT in patients with cN0 breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynecology, Multidisciplinary Breast Cancer Unit, Hospital Universitari Bellvitge, Idibell, c/ Feixa Llarga s/n. Hospitalet de Llobregat, CP: 08907, Barcelona, Spain. sfernandezg@bellvitgehospital.cat.
- Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Feixa Llarga, s/n, 08907, l'Hospitalet de Llobregat, Spain. sfernandezg@bellvitgehospital.cat.
- Department of Medical Oncology, Multidisciplinary Breast Cancer Unit, Institut Català d'Oncologia, Idibell, Barcelona, Spain.
- Department of Gynecology, Multidisciplinary Breast Cancer Unit, Hospital Universitari Bellvitge, Idibell, c/ Feixa Llarga s/n. Hospitalet de Llobregat, CP: 08907, Barcelona, Spain.
- Department of Radiology, Multidisciplinary, Breast Cancer Unit. Hospital Universitari Bellvitge, Idibell, Barcelona, Spain.
- Department of Pathology, Multidisciplinary Breast Cancer Unit, Hospital Universitari Bellvitge, Idibell, Barcelona, Spain.
Förderung
- Universitat de Barcelona
Zitieren
APA
Fernandez-Gonzalez, S., Falo, C., Pla, M. J., Campos, M., Ortega-Exposito, C., Ortega, R., Vicente, M., Petit, A., Bosch-Schips, J., Bajen, M. T., Reyes, G., Martínez, E., González-Viguera, J., Peñafiel, J., Stradella, A., Pernas, S., Ponce, J., & Garcia-Tejedor, A. (2024). Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival—a propensity score cohort study. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07274-1
Vancouver
Fernandez-Gonzalez S, Falo C, Pla MJ, Campos M, Ortega-Exposito C, Ortega R, et al. Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival—a propensity score cohort study. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07274-1
BibTeX
@article{FernandezGonzalez2024,
author = {Fernandez-Gonzalez, Sergi and Falo, Catalina and Pla, Maria J and Campos, Miriam and Ortega-Exposito, Carlos and Ortega, Raul and Vicente, Maria and Petit, Ana and Bosch-Schips, Jan and Bajen, Maria Teresa and Reyes, Gabriel and Martínez, Evelyn and González-Viguera, Javier and Peñafiel, Judith and Stradella, Agostina and Pernas, Sonia and Ponce, Jordi and Garcia-Tejedor, Amparo},
title = {Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival—a propensity score cohort study},
journal = {Breast Cancer Research and Treatment},
year = {2024},
doi = {10.1007/s10549-024-07274-1}
}
EUVIMED